Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin J Am Soc Nephrol
Главные авторы: Thompson, Aliza, Carroll, Kevin, A. Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W. Major, Rupert, I. Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C., S. Gillespie, Barbara, Kausz, Annamaria, W. Mercer, Alex, Reich, Heather N., H. Rovin, Brad, West, Melissa, Nachman, Patrick H.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Nephrology 2019
Предметы:
Feature
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
https://ncbi.nlm.nih.gov/pubmed/30635299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08600718
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы